Local Control of Disease Related to Lymph Node Involvement in Non-Small Cell Lung Cancer After Sleeve Lobectomy Compared With Pneumonectomy

Kim, Young Tae; Kang, Chang Hyun; Sung, Sook Whan; Kim, Joo Hyun

doi:10.1016/j.athoracsur.2004.09.011

Cited by 82 publications

(106 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For this study, we examined the marker in sputum samples from individuals who had undergone curative resection for stage I NSCLC and who were disease-free for at least 6 months before sputum sample collection ( from 6 to 36 months). These individuals are known to develop, by 3 years, tumor recurrence and/or second lung tumors at the rate of 20% to 38% postsurgery (31)(32)(33). In these individuals, 79% of specimens were judged cytologically adequate and, strikingly, ASC/TMS1 promoter methylation in sputum was present in 23.8% (10 of 42) of the patients (P V 0.05, compared with the high-risk smokers).…”

Section: Resultsmentioning

confidence: 99%

Hypermethylation of ASC/TMS1 Is a Sputum Marker for Late-Stage Lung Cancer

et al. 2006

View full text Add to dashboard Cite

DNA hypermethylated gene promoter sequences are extremely promising cancer markers. Their use for risk assessment, early diagnosis, or prognosis depends on the timing of this gene change during tumor progression. We studied this for the proapoptotic gene ASC/TMS1 in lung cancer and used the findings to develop a sputum marker. ASC/TMS1 protein levels are reduced in all lung cancer types (30 of 40; 75%) but not in 10 preinvasive lesions. Hypermethylation of ASC/TMS1 is also associated with invasive cancers (41 of 152 or 27.0% of all lung cancer types) with variation in incidence between histopathologic types including 32.1% (26 of 81) of adenocarcinomas, 13.2% (7 of 53) of squamous cell carcinomas, 38.5% (5 of 13) of large-cell carcinomas, and 60% (3 of 5) of small-cell lung cancers. The hypermethylation is particularly correlated with late tumor stages being present in only 14% of stage I but 60% of later-stage tumors. The incidence of ASC/TMS1 hypermethylation in sputum DNA fully mimics the tissue findings being present in only 2% (2 of 85) of high-risk, cancerfree smokers, 15% (3 of 18) of patients with stage I non-smallcell lung cancer (NSCLC), but 41% of patients with stage III NSCLC (18 of 44), including 56% (10 of 18) of those with adenocarcinoma. Importantly, sputum is positive for this marker in 24% (10 of 42) of very high risk, clinically cancerfree individuals previously resected for stage I NSCLC. Thus, hypermethylation of ASC/TMS1 is a marker for late-stage lung cancer and, in sputum, could predict prognosis in patients resected for early-stage disease. (Cancer Res 2006; 66(12): 6210-8)

show abstract

Section: Resultsmentioning

confidence: 99%

Hypermethylation of ASC/TMS1 Is a Sputum Marker for Late-Stage Lung Cancer

et al. 2006

View full text Add to dashboard Cite

show abstract

“…This is similar to other studies which report crude brain metastases rates ranging from 2% to 16% for stage I disease 12,18-26 and 3% to 19 % for stage II disease. 24,[26][27][28][29][30] Second, although the overall rate was low, brain metastases developed in 29% patients who failed at distant sites. Thus, future efforts to reduce the risk of distant recurrence will need to account for failures in the central nervous system.…”

Section: Discussionmentioning

confidence: 99%

Factors associated with the development of brain metastases

Hubbs

Boyd

Hollis

et al. 2010

Cancer

114

View full text Add to dashboard Cite

BACKGROUND The risk of developing brain metastases after definitive treatment of locally advanced nonsmall cell lung cancer (NSCLC) is approximately 30%-50%. The risk for patients with early stage disease is less defined. The authors sought to investigate this further and to study potential risk factors. METHODS The records of all patients who underwent surgery for T1-T2 N0-N1 NSCLC at Duke University between the years 1995 and 2005 were reviewed. The cumulative incidence of brain metastases and distant metastases was estimated by using the Kaplan-Meier method. A multivariate analysis assessed factors associated with the development of brain metastases. RESULTS Of 975 consecutive patients, 85% were stage I, and 15% were stage II. Adjuvant chemotherapy was given to 7%. The 5-year actuarial risk of developing brain metastases and distant metastases was 10%(95% confidence interval [CI], 8-13) and 34%(95% CI, 30-39), respectively. Of patients developing brain metastases, the brain was the sole site of failure in 43%. On multivariate analysis, younger age (hazard ratio [HR], 1.03 per year), larger tumor size (HR, 1.26 per cm), lymphovascular space invasion (HR, 1.87), and hilar lymph node involvement (HR, 1.18) were associated with an increased risk of developing brain metastases. CONCLUSIONS In this large series of patients treated surgically for early stage NSCLC, the 5-year actuarial risk of developing brain metastases was 10%. A better understanding of predictive factors and biological susceptibility is needed to identify the subset of patients with early stage NSCLC who are at particularly high risk. Cancer 2010;116:5038-46.

show abstract

“…In addition, it is technically more challenging due to high risk of positive bronchial margin for T3 (central) compared with T1 and T2. For T4 disease, it is poor candidate for SL (15). The presence of N2 significantly impairs long-term outcomes among sleeve lobectomies due to systemic recurrences (16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy?

Ma¹,

Guo²,

Shu³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Pneumonectomy (PN) has traditionally been the treatment of choice for central lung tumors for which the alternative is sleeve lobectomy (SL). The aim of this study was to compare early and long-term results after SL and PN in focusing on T3 central non-small cell lung cancer (NSCLC). Methods:Patients who underwent SL (n=58) or PN (n=42) were retrospectively analyzed. For bias reduction, these 100 patients had been selected according to the following criteria: (I) tumor located in the main bronchus less than 2 cm distal to the carina; (II) there were no N2 disease; (III) no induction therapy was applied; (IV) complete resection (R0) was achieved. It is an adequate oncologic resection and should be treated as the first line intervention whenever complete resection can be achieved.

show abstract

Local Control of Disease Related to Lymph Node Involvement in Non-Small Cell Lung Cancer After Sleeve Lobectomy Compared With Pneumonectomy

Cited by 82 publications

References 14 publications

Hypermethylation of ASC/TMS1 Is a Sputum Marker for Late-Stage Lung Cancer

Hypermethylation of ASC/TMS1 Is a Sputum Marker for Late-Stage Lung Cancer

Factors associated with the development of brain metastases

For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy?

Contact Info

Product

Resources

About